

What do we know about managing early NSCLC?

Allan Price

NHS Lothian/

University of Edinburgh

What do we know about managing early NSCLC – *disclosures*

- Research support
 - AstraZeneca
 - Biomira
 - Bioven
 - Boehringer Ingelheim
 - Lilly Oncology
 - Merck,
 - MolMed S.p.A.
 - OSI Pharmaceuticals
 - Pfizer a
 - Sanofi Aventis

What do we know about managing early NSCLC – *stage I-II*?

- Which operation is best?
- What are the safe limits of cardiopulmonary reserve?
- Which adjuvant regimens for which patients - *Bepler*?
- What doses and how many cycles are necessary - *Bepler*?
- Is there a role for targeted agents - *Gautschi*?
- Are there patients better treated by radiotherapy – *de Ruysscher*?
- If so, what dose or fractionation – *de Ruysscher*?

What do we know about managing early NSCLC – *stage III*?

- What radiotherapy dose is best – *de Ruysscher*?
- Which radiotherapy fractionation is best – *de Ruysscher*?
- What are the safe limits of cardiopulmonary reserve?
- Which chemotherapy regimens for which patients – *Bepler*?
- What doses and how many cycles are necessary – *Bepler*?
- Is there a role for targeted agents – *Gautschi*?
- Is there a role for surgery – *Stamatis*?
- Should we use prophylactic cranial irradiation?

What do we know about managing early NSCLC?

- Are there any biological predictive factors which might influence these decisions?
 - Proteomics not genomics?
 - ENCODE Project Consortium 2012
 - Exome 1-2% genome
 - Regulatory sequences 40% genome?
 - Cancer Genome Atlas Research Network 2012
 - 178 squamous lung cancers
 - 360 exon mutations
 - 165 genomic rearrangements
 - 323 copy number alteration

What do we know about managing early NSCLC?

- Is our current research paradigm fit for purpose?
 - Pharmacovigilance
 - Paucity of trial participants
 - Lead time from idea to clinic
 - Industry & academia